Bridging Discoveries to Practice—CCO’s Conference to Clinic Highlights From the 2024 ASH Annual Meeting *

Review a preview ClinicalThought commentary, on-demand webcasts, and slidesets highlighting key studies from the 2024 ASH annual meeting.

Share

Program Content

Events

Activities

ASH 2024 Preview
An Expert’s Guide to ASH 2024: Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2024

Expires: December 04, 2025

6 Capsule Summary Slidesets

Activities

RATIFY 10-Yr Follow-Up
CALGB 10603/RATIFY: 10-Yr Follow-up of Midostaurin vs Placebo Combined With Intensive CT for Newly Diagnosed FLT3-Mutant AML 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2024

Expires: December 09, 2025

ASC4FIRST Asciminib
ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor as First-line Therapy for Chronic Myeloid Leukemia in Chronic Phase
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

ASCEND CML
ASCEND-CML: Update From Phase II Trial of Frontline Asciminib in Patients With CP-CML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

CLAD LDAC VEN in ND AML
Phase II Trial of Cladribine + LDAC + Venetoclax Alternating With Azacitidine + Venetoclax in Patients With Newly Diagnosed AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

GIMEMA ALL2820
GIMEMA ALL2820: Intermediate Analysis of Phase III Trial of First-line Ponatinib + Blinatumomab in Adults With Ph+ Acute Lymphoblastic Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

Revumenib in Acute Leukemias
AUGMENT-101 and SAVE: Revumenib-Based Therapy in R/R Acute Leukemias
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: December 15, 2025

7 Capsule Summary Slidesets

Activities

AZD0486 for RR FL
AZD0486, a CD19 x CD3 Bispecific Antibody, for Relapsed/Refractory Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2024

Expires: December 08, 2025

MITHIC FL1 Mosunetuzumab
MITHIC-FL1: Phase II Study of Single-Agent Mosunetuzumab in Patients With Newly Diagnosed Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2024

Expires: December 08, 2025

BRUIN CLL-321
BRUIN CLL-321: Phase III Trial of Pirtobrutinib vs Idelalisib + Rituximab or Bendamustine + Rituximab in Covalent BTK Inhibitor–Pretreated CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

ALTAMIRA
ALTAMIRA: Phase II Trial of Acalabrutinib + Rituximab as First-line Treatment for Mantle Cell Lymphoma in Patients Aged ≥60 Yr
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

inMIND
inMIND: A Phase III Study of Tafasitamab, an Anti-CD19 Antibody, Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

ECOG ACRIN EA4151
ECOG-ACRIN EA4151: Phase III Trial of Autologous Hematopoietic Cell Transplantation in MRD-Negative Patients With Mantle Cell Lymphoma in First Complete Remission
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

AMPLIFY
AMPLIFY: First-line Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab vs CIT in CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

6 Capsule Summary Slidesets

Activities

DREAMM 7 Belantamab Combo
DREAMM-7 Efficacy Update: Belantamab Mafodotin Plus Bortezomib, Dexamethasone vs Daratumumab Plus Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

Mezigdomide Plus Vd or Kd for RRMM
Mezigdomide Plus Vd or Kd in Relapsed/Refractory Multiple Myeloma: Updated Results From the CC-92480-MM-002 Phase I/II Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

Arlocabtagene Autoleucel
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-cell Therapy, in Heavily Pretreated Multiple Myeloma: Updated Phase I Study Results
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

IFM2017-03: Dara Len in Frail ND MM
IFM2017-03: Phase III Trial of Daratumumab Plus Lenalidomide Without Long-term Dexamethasone vs Lenalidomide and Dexamethasone in Frail Patients With Newly Diagnosed MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

MajesTEC 4
EMN30/MajesTEC-4: Safety Run-in Data From Phase III Trial of Teclistamab ± Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma After ASCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

AQUILA Daratumumab
AQUILA: Primary Results From the Phase III Trial of Daratumumab vs Active Monitoring for High-Risk Smoldering Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

6 Capsule Summary Slidesets

Activities

COMMANDS Luspatercept
COMMANDS: Long-term Outcomes of the Phase III Trial of Luspatercept vs Epoetin alfa for ESA-Naive, Transfusion-Dependent, Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2024

Expires: December 08, 2025

GFM COMBOLA
GFM COMBOLA Part A: Phase I/II Study of Luspatercept + EPO in Patients With Lower-Risk, Ring Sideroblast–Negative MDS After ESA Failure
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2024

Expires: December 09, 2025

IMerge Pooled Analysis
IMerge Pooled Analysis: Effect of Previous Treatments on Imetelstat Activity in RBC Transfusion–Dependent LR-MDS Relapsed/Refractory to ESAs
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2024

Expires: December 09, 2025

Early vs Late ESA for Anemia in Lower Risk MDS
EPO-PRETAR: Phase III Trial of Early vs Late Initiation of ESA Treatment in Patients With Lower-Risk MDS and Anemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2024

Expires: December 09, 2025

BOREAS
BOREAS: Phase III Trial of Navtemadlin vs Best Available Therapy in Patients With JAK Inhibitor R/R Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

DAC + ATRA for MDS EB
Decitabine Plus ATRA for Newly Diagnosed MDS With Excessive Blasts
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: December 15, 2025

6 Capsule Summary Slidesets

Activities

Axatilimab Response Analysis
AGAVE-201 Response Analysis: Axatilimab for Patients With Chronic GVHD
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2024

Expires: December 08, 2025

Pimicotinib in cGVHD
Phase II Trial of Pimicotinib, a CSF-1R Inhibitor, for Previously Treated Chronic GVHD
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2024

Expires: December 09, 2025

LUNA 3: Rilzabrutinib in ITP
LUNA 3: Phase III Trial of Rilzabrutinib vs Placebo in Patients Aged ≥18 Yr With Persistent/Chronic Primary ITP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

VAYHIT3 Trial of Ianalumab
Phase II VAYHIT3 Interim Results: Ianalumab in Previously Treated Primary Immune Thrombocytopenia 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

ELA026 in sHLH
Phase Ib Study of ELA026, an Anti-SIRP-α/β/γ mAb, in Patients With Secondary Hemophagocyctic Lymphohistiocytosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

Rovadicitinib in Chronic GVHD
Updated Results From a Phase Ib/IIa Trial of Rovadicitinib for Glucocorticoid-Refractory or Dependent Chronic Graft-vs-Host Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: December 15, 2025

Faculty

cover img faculity

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Catherine M. Broome, MD

Professor of Medicine
MedStar Georgetown University Hospital
Lombardi Cancer Center
Washington, DC

cover img faculity

Jonathon B. Cohen, MD, MS

Co-Director Lymphoma Program
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

cover img faculity

Corey Cutler, MD, MPH

Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Rami Komrokji, MD

Vice Chair of Malignant Hematology Department
Senior Member and Professor of Oncologic Sciences
H. Lee Moffitt Cancer Center
University of South Florida
Tampa, Florida

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

cover img faculity

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.